NASDAQ:ARCT
Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc.'s revenue fell 46.1% in fiscal 2025 to $82.0M while operating margin fell to −93.0%. Free cash flow was −$74.5M, −90.8% of revenue, and the diluted share count rose 1.4%.Summary generated from Arcturus Therapeutics Holdings Inc.'s SEC filings. Latest annual report filed Mar 3, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$82.0M
Revenue growth−46.1%
Revenue, 5-yr CAGR+53.8%
Gross marginn/a
Operating margin−93.0%
Net margin−80.2%
ROICn/a
Return on equity−28.9%
Debt / equityn/a
Free cash flow−$74.5M
FCF margin−90.8%
Share count change+1.4%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 12 | 206 | 167 | 152 | 82 |
| Operating income | −203 | 12 | −78 | −96 | −76 |
| Net income | −204 | 9 | −30 | −81 | −66 |
| Free cash flow | −138 | 24 | −21 | −60 | −75 |
Recent filings
- 8-KRegulation FD disclosure
Sep 23, 2026 - 8-KRegulation FD disclosure
Aug 25, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KEntry into a material agreement
Jul 2, 2026 - 4Insider transaction report
Jun 15, 2026 - 4Insider transaction report
Jun 15, 2026 - 8-KResults of a shareholder vote
Jun 5, 2026